Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Journal of Managed Care Pharmacy : JMCP|November 19, 2004
Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart auditJacob Abarca, Daniel C Malone, Edward P Armstrong, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 1, 2014
RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studiesTabitha N Kung, Jessica Dennis, Yiqing Ma, et al.
British Journal of Clinical Pharmacology|April 6, 2021
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjectsAntonia Davidson, Darin Brimhall, Jonathan Kay, et al.
International Journal of Rheumatic Diseases|July 26, 2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesRoy Fleischmann, Joel Kremer, Yoshiya Tanaka, et al.
RMD Open|January 21, 2020
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritisJosef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
The Journal of Rheumatology|January 1, 2003
Temporal artery bruits in a patient with giant cell arteritisScott T Persellin, Marc D Cohen, William W Ginsburg, et al.
Journal of the American Academy of Dermatology|April 26, 2006
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosisRobert M Knobler, Lars E French, Youn Kim, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
The Journal of Rheumatology|November 17, 2010
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexateMichael E Weinblatt, Edward C Keystone, Marc D Cohen, et al.
Pageof 10